Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 1/20 | 0.55 |
| ▸ | MDM2 | Q00987 | 6/20 | 0.54 |
| ▸ | MDM4 | O15151 | 1/20 | 0.52 |
| ▸ | TP53 | P04637 | 1/20 | 0.52 |
| ▸ | TLR2 | O60603 | 2/20 | 0.52 |
| ▸ | C3AR1 | Q16581 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31647336 | 1.00 | KMT2A (0.55) | KMT2AMDM2MDM4TP53TLR2 | |
| SCHEMBL29569815 | 1.00 | KMT2A (0.55) | KMT2AMDM2MDM4TP53TLR2 | |
| SCHEMBL119468 | 1.00 | KMT2A (0.55) | KMT2AMDM2MDM4TP53TLR2 | |
| SCHEMBL29362229 | 1.00 | KMT2A (0.55) | KMT2AMDM2MDM4TP53TLR2 | |
| SCHEMBL29850382 | 1.00 | KMT2A (0.55) | KMT2AMDM2MDM4TP53TLR2 | |
| SCHEMBL13401519 | 1.00 | KMT2A (0.55) | KMT2AMDM2MDM4TP53TLR2 | |
| SCHEMBL29401148 | 1.00 | KMT2A (0.55) | KMT2AMDM2MDM4TP53TLR2 | |
| SCHEMBL4600663 | 0.97 | KMT2A (0.56) | KMT2AMDM2MDM4TP53TLR2 | |
| SCHEMBL4882849 | 0.97 | KMT2A (0.56) | KMT2AMDM2MDM4TP53TLR2 | |
| SCHEMBL29401108 | 0.97 | KMT2A (0.56) | KMT2AMDM2MDM4TP53TLR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230257343-A1 | NOVEL AMINO ACID DERIVATIVES | PEPTIDREAM INC (JP) | 2023-08-17 | — | — | US | claimed |
| CN-110776555-B | Difunctional D-amino acid modified opioid peptide compound and synthetic method and application thereof | 王锐 | 2023-10-13 | — | — | CN | disclosed |
| US-20230257343-A1 | NOVEL AMINO ACID DERIVATIVES | PEPTIDREAM INC (JP) | 2023-08-17 | — | — | US | disclosed |
| US-20230257343-A1 | NOVEL AMINO ACID DERIVATIVES | PEPTIDREAM INC (JP) | 2023-08-17 | — | — | US | disclosed |
| CN-114917361-A | Antibody Drug Conjugates (ADC) and antibody prodrug conjugates (APDC) with enzyme cleavable groups | 拜耳医药股份有限公司 | 2022-08-19 | — | — | CN | disclosed |
| CN-106163568-B | Antibody Drug Conjugates (ADC) containing spindle Kinesin (KSP) | 拜耳制药股份公司 | 2021-03-23 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230257343-A1 | NOVEL AMINO ACID DERIVATIVES | DNPEP, BCAT1, ANPEP | KMT2A 3083/4885MDM2 423/4885MDM4 1648/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.